ENTRADA THERAPEUTICS, INC. Restricted Cash
ENTRADA THERAPEUTICS, INC. (TRDA) had Restricted Cash of $4.00 million as of 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2023-03-06
- 2022-12-31: Restricted Cash $4.00M.
- 2022-09-30: Restricted Cash $3.95M.
- 2022-06-30: Restricted Cash $3.95M.
- 2022-03-31: Restricted Cash $3.95M.
| Period end | Restricted Cash |
|---|---|
| 2022-12-31 | $4.00M 10-K · filed 2023-03-06 |
| 2022-09-30 | $3.95M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $3.95M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.95M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |